Dr. Reddy’s Laboratories Ltd is a leading India-based pharamceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.
Financial Results:
Dr Reddys Laboratories Ltd reported Revenues for Q2FY24 of ₹6,903.00 Crores up from ₹6,332.00 Crore year on year, a rise of 9.02%.
Total Expenses for Q2FY24 of ₹5,305.00 Crores up from ₹4,773.00 Crores year on year, a rise of 11.15%.
Consolidated Net Profit of ₹1,482.00 Crores up 33.03% from ₹1,114.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹88.87, up 32.78% from ₹66.93 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.